Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2026)
Avalo Therapeutics (AVTX) reported Deferred Taxes of $12000.0 for Q1 2026, up 50.0% on a YoY basis from $8000.0 in Q1 2025, and down 90.84% quarter-over-quarter from $131000.0 in Q4 2025.
Avalo Therapeutics (AVTX) Deferred Taxes (2017 - 2026) Analysis & Trends
Avalo Therapeutics has reported Deferred Taxes for 10 years, with the latest figure at $12000.0 in Q1 2026.
- For the quarter ending Q1 2026, Deferred Taxes rose 50.0% year-over-year to $12000.0; the trailing twelve-month figure through Mar 2026 stood at $169000.0 (up 46.96% YoY), and the FY2025 full-year result was $165000.0, up 44.74% from the prior year.
- Deferred Taxes for Q1 2026 stood at $12000.0, down from $131000.0 in the prior quarter.
- The five-year high for Deferred Taxes was $131000.0 in Q4 2025, with the low at -$14000.0 in Q3 2024.
- Historically, Deferred Taxes has averaged $19588.2 across 5 years, with a median of $8000.0 in 2022.
- The largest YoY upside for Deferred Taxes was 1366.67% in 2024 against a maximum downside of 275.0% in 2024.
- Avalo Therapeutics' Deferred Taxes stood at $8000.0 in 2022, then tumbled by 212.5% to -$9000.0 in 2023, then soared by 1366.67% to $114000.0 in 2024, then rose by 14.91% to $131000.0 in 2025, then tumbled by 90.84% to $12000.0 in 2026.
- The last three Deferred Taxes figures came in at $12000.0 (Q1 2026), $131000.0 (Q4 2025), and $10000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -65.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - | 12,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12,000.00 |
| Dec 31, 2025 | 131,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 16,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | 7,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | 8,000.00 |
| Sep 30, 2022 | 5,000.00 |
| Jun 30, 2022 | 6,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | -62,000.00 |
| Sep 30, 2021 | 9,000.00 |
| Jun 30, 2021 | 10,000.00 |